Telangiectasia, Hereditary Hemorrhagic Clinical Trial
Official title:
A Phase II Study to Evaluate the Effects of up to 12 Weeks of Pazopanib Dosing on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia
This study will investigate whether pazopanib can reduce epistaxis and improve anaemia in subjects with hereditary haemorrhagic telangiectasia (HHT) at a dose that is well tolerated. The study will have 2 parts. Part A will be an open label, dose-escalation study in which up to 4 cohorts of approximately 6 subjects each will receive increasing doses of pazopanib for a maximum of 12 weeks. The dose in the first cohort will be 50mg per day and the maximum dose in a cohort will be 400 mg per day. Dose escalation will not occur as planned if the predefined safety stopping criteria are met or at least 4 subjects in a cohort have demonstrated efficacy (as measured by epistaxis, haemoglobin, transfusion or iron infusion requirements). If efficacy is demonstrated in Part A with an acceptable safety profile, Part B will be initiated to further define the optimal dose(s) including dose duration/schedule and to provide further support for the proof of mechanism. Approximately 15 subjects will participate and will be randomised to active or placebo in a ratio of 3:2. This part of the study will be double-blind.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03227263 -
BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).
|
Phase 3 | |
| Completed |
NCT00733655 -
Study of Histological Samples From Patients With Hereditary Haemorrhagic Telangiectasia
|
||
| Completed |
NCT00355108 -
ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome
|
Phase 3 | |
| Completed |
NCT01507480 -
The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia
|
Phase 1 | |
| Completed |
NCT03910244 -
Pomalidomide for the Treatment of Bleeding in HHT
|
Phase 2 | |
| Completed |
NCT04108052 -
Diagnostic Value of Ultra-low Dose Thoracic Scanner for the Pulmonary Arteriovenous Malformation Detection in HHT Patient
|
N/A | |
| Recruiting |
NCT04976036 -
Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients
|
Phase 2 | |
| Completed |
NCT00684879 -
Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia
|
||
| Completed |
NCT00004648 -
Studies of Hereditary Hemorrhagic Telangiectasia
|
N/A | |
| Completed |
NCT00230672 -
Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs
|
||
| Completed |
NCT03954782 -
Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.
|
Phase 2 | |
| Completed |
NCT02484716 -
Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)
|
Phase 2 | |
| Recruiting |
NCT00230685 -
Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia
|
||
| Recruiting |
NCT00230620 -
Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families
|
||
| Recruiting |
NCT02157987 -
Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose
|
Phase 1/Phase 2 | |
| Completed |
NCT01408030 -
North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
|
Phase 2 | |
| Completed |
NCT00230659 -
Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia
|
||
| Withdrawn |
NCT00733629 -
Study of Endothelial Cells in Patients With Hereditary Haemorrhagic Telangiectasia
|
||
| Active, not recruiting |
NCT00230633 -
Studies of White Blood Cells Derived From HHT Patients
|
||
| Recruiting |
NCT05933330 -
Hereditary Hemorrhagic Telangiectasia and Neurovascular Manifestations, in the Danish HHT Database
|